Pediatric and Geriatric Clinical Trials

Informed Consent and Assent in Pediatric and Geriatric Clinical Trials

Posted on digi By digi

Informed consent is a foundational ethical and legal requirement in clinical research. It ensures that participants—or their legal representatives—understand the nature, risks, and benefits of the trial before agreeing to participate. In pediatric and geriatric clinical trials, the consent process must be adapted to the specific cognitive, emotional, and situational needs of these vulnerable populations.
Click to read the full article.

Age-Specific Protocol Design, Pediatric and Geriatric Clinical Trials

Recruitment and Retention Strategies for Pediatric and Geriatric Clinical Trials

Posted on digi By digi

Recruiting and retaining participants in clinical trials is a complex process, especially in pediatric and geriatric populations. These groups face unique barriers, ranging from parental consent in children to health-related limitations in older adults. Successful recruitment strategies must be ethically sound, culturally sensitive, and logistically feasible, while retention strategies must ensure ongoing participant engagement and compliance throughout the study.
Click to read the full article.

Age-Specific Protocol Design, Pediatric and Geriatric Clinical Trials

Safety Monitoring in Pediatric and Geriatric Clinical Trials

Posted on digi By digi

Safety monitoring is a critical aspect of clinical trials, especially when involving vulnerable populations such as children and elderly adults. These groups have unique physiological and pharmacological profiles that can influence drug metabolism, tolerability, and susceptibility to adverse effects. Pediatric trials must consider developmental stages, while geriatric trials must account for comorbidities, polypharmacy, and age-related physiological changes.
Click to read the full article.

Age-Specific Protocol Design, Pediatric and Geriatric Clinical Trials

Determining Maximum Tolerated Dose in Elderly Clinical Trial Participants

Posted on digi By digi

Determining a maximum tolerated dose (MTD) in older adults is not a simple transplant of adult protocols into a geriatric population. Physiological changes that accompany aging—reduced renal and hepatic clearance, altered body composition, and diminished homeostatic reserve—shift the exposure–toxicity curve. Coexisting illnesses and polypharmacy compound this effect, creating a narrower therapeutic window and a higher baseline risk for dose-limiting toxicities (DLTs). The practical implication is that a dose proven “tolerable” in a younger adult cohort may overexpose an 80-year-old with eGFR 45 mL/min/1.73 m² and a medication list of ten agents.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Determining Maximum Tolerated Dose in Elderly Clinical Trial Participants

Posted on digi By digi

In older adults, the “maximum tolerated dose” (MTD) is rarely the same as in younger or mixed adult populations. Physiological aging changes everything from drug absorption and plasma protein binding to hepatic metabolism and renal elimination. Add common geriatric realities—polypharmacy, multimorbidity, sarcopenia, autonomic dysfunction, and reduced homeostatic reserve—and you get a markedly narrower therapeutic window. That means a dose that looks “safe” in a 50‑year‑old may tip an 80‑year‑old into clinically meaningful toxicity long before it hits classic grade 3/4 lab thresholds. Practically, an elderly participant’s orthostatic hypotension with near‑falls, intermittent confusion, or functional decline can be more relevant than a transient lab blip. Therefore, MTD in geriatrics must be anchored to outcomes that matter to older adults, not just canonical laboratory toxicities.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Therapeutic Drug Monitoring in Neonates: A Trialist’s Handbook for Safe, Precise Dosing

Posted on digi By digi

Neonates—especially preterm infants—present the steepest pharmacokinetic (PK) gradients in human development. Glomerular filtration increases several‑fold in weeks, hepatic enzyme systems switch on with ontogeny, albumin and α1‑acid glycoprotein concentrations change rapidly, and body water compositions are extreme relative to adults. As a result, a fixed milligram‑per‑kilogram dose that appears adequate on day 3 of life may be subtherapeutic by day 14, or vice versa. This dynamism makes therapeutic drug monitoring (TDM) not a convenience, but a core safety and efficacy control in neonatal clinical trials. TDM provides an empirical exposure check to avoid toxicity (e.g., aminoglycoside ototoxicity) and to ensure target attainment (e.g., time above MIC for beta‑lactams or AUC/MIC for vancomycin).
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Use of Body Surface Area vs Weight in Dosing

Posted on digi By digi

Whether to dose by body surface area (BSA; mg/m²) or by body weight (mg/kg) is not a cosmetic protocol choice—it directly influences exposure, safety, feasibility, and even recruitment. BSA historically emerged from oncology, where drug clearance seemed to correlate with metabolic rate approximated by surface area. Weight-based dosing, by contrast, aligns with contemporary pharmacometric practice, is operationally simpler in multicenter trials, and often matches label conventions for anti-infectives and supportive care medicines. In children, rapid changes in body composition, organ maturation, and growth make a one-size-fits-all rule risky: a 4‑kg neonate and a 35‑kg adolescent have different physiologies despite similar “per kg” arithmetic. In older adults, sarcopenia, edema, and altered fat/water compartments complicate both BSA and weight metrics; an 80‑year‑old with edema may appear “heavier” without proportional metabolic capacity, risking overexposure under mg/kg dosing.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Safety Monitoring Committees for Vulnerable Populations

Posted on digi By digi

Safety Monitoring Committees—commonly called Data Safety Monitoring Boards (DSMBs) or Data Monitoring Committees (DMCs)—are not just governance niceties. In pediatric and geriatric studies, they are the primary mechanism for balancing scientific learning against the unique risks of developmental immaturity and age-related frailty. Children differ from adults in ontogeny of metabolic enzymes, body-water composition, and immune maturation; older adults face polypharmacy, multimorbidity, reduced renal/hepatic reserve, and higher baseline risk of falls or delirium. These population factors reshape what qualifies as a “clinically meaningful” adverse event. A DSMB that understands those nuances will tune interim analyses, dose-escalation gates, and stopping rules to the biology at hand rather than blindly reusing adult templates.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Cumulative Toxicity Monitoring in Aging Subjects

Posted on digi By digi

Cumulative toxicity refers to injury that emerges from repeated or sustained exposure rather than from a single dose. In aging participants, the risk trajectory is steeper because baseline organ reserve (renal, hepatic, bone marrow, cardiac) is reduced and recovery from reversible injury is slower. Polypharmacy, multimorbidity, sarcopenia, and altered pharmacokinetics (PK) and pharmacodynamics (PD) further narrow the therapeutic window. Practically, this means that standard per‑cycle safety checks may miss a slowly rising exposure curve or a progressive functional decline that is invisible in isolated lab values. A participant can complete three cycles without grade ≥3 lab abnormalities yet accumulate fatigue, orthostatic hypotension, and subclinical creatinine rise that culminate in hospitalization during cycle four. Cumulative monitoring reframes safety from “Did an event occur?” to “How is risk changing over time as exposure accrues?”—and that framing is central to geriatric drug development.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials

Pharmacovigilance Strategies for Geriatric Clinical Trials

Posted on digi By digi

Pharmacovigilance (PV) in geriatric trials cannot be a copy‑paste of general adult methods. Aging changes the baseline risk profile—renal and hepatic reserve decline, autonomic responses blunt, and homeostatic buffers narrow. Add multimorbidity and polypharmacy, and you get atypical adverse drug reactions (ADRs) that present as falls, delirium, orthostatic hypotension, or functional decline rather than classic grade 3–4 laboratory shifts. If the PV system tracks only lab abnormalities and “textbook” events, it will miss the signals that matter to independence and outcomes in older adults.
Click to read the full article.

Dosing and Safety Assessments, Pediatric and Geriatric Clinical Trials